...
首页> 外文期刊>Molecular Neurobiology >MicroRNA-Directed Neuronal Reprogramming as a Therapeutic Strategy for Neurological Diseases
【24h】

MicroRNA-Directed Neuronal Reprogramming as a Therapeutic Strategy for Neurological Diseases

机译:MicroRNA-定向神经元重编程作为神经疾病的治疗策略

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The loss of neurons due to injury and disease results in a wide spectrum of highly disabling neurological and neurodegenerative conditions, given the apparent limited capacity of endogenous repair of the adult central nervous system (CNS). Therefore, it is important to develop technologies that can promote de novo neural stem cell and neuron generation. Current insights in CNS development and cellular reprogramming have provided the knowledge to finely modulate lineage-restricted transcription factors and microRNAs (miRNA) to elicit correct neurogenesis. Here, we discuss the current knowledge on the direct reprogramming of somatic non-neuronal cells into neural stem cells or subtype specific neurons in vitro and in vivo focusing on miRNA driven reprogramming. miRNA can allow rapid and efficient direct phenotype conversion by modulating gene networks active during development, which promote global shifts in the epigenetic landscape pivoting cell fate decisions. Furthermore, we critically present state-of-the-art and recent advances on miRNA therapeutics that can be applied to the diseased CNS. Together, the advances in our understanding of miRNA role in CNS development and disease, recent progress in miRNA-based therapeutic strategies, and innovative drug delivery methods create novel perspectives for meaningful therapies for neurodegenerative disorders.
机译:鉴于成人中枢神经系统(CNS)内源性修复的表观限制能力,由于损伤和疾病导致神经元引起的神经元的丧失导致宽度的高度禁用神经变性条件。因此,开发能够促进De Novo神经干细胞和神经元发电的技术非常重要。 CNS开发和蜂窝重新编程的当前见解提供了精细调节谱系限制的转录因子和MicroRNA(miRNA)以引发正确神经发生的知识。在这里,我们讨论了关于在体外重新编程到神经干细胞或亚型特异性神经元的目前的知识,体外和体内聚焦MiRNA驱动重编程。 MiRNA可以通过调节在开发过程中激活的基因网络来允许快速和有效的直接表型转化,这促进了表观遗传景观枢转细胞命运决策的全局变化。此外,我们批判性地提出了最新的和最近可以应用于患病CNS的miRNA治疗剂的进展。我们在CNS开发和疾病中了解MiRNA作用的进展,最近基于MiRNA的治疗策略的进展,创新的药物递送方法为神经变性障碍的有意义疗法创造了新的视角。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号